Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amlodipine/telmisartan/hydrochlorothiazide - Boehringer Ingelheim/Astellas Pharma

Next Previous
Search
Drug Profile

Amlodipine/telmisartan/hydrochlorothiazide - Boehringer Ingelheim/Astellas Pharma

Alternative Names: Amlodipine besylate/telmisartan/hydrochlorothiazide; Amlodipine/hydrochlorothiazide/telmisartan; Hydrochlorothiazide/amlodipine/telmisartan; Hydrochlorothiazide/telmisartan/amlodipine; Micatrio; Telmisartan/amlodipine/hydrochlorothiazide; Telmisartan/hydrochlorothiazide/amlodipine

Latest Information Update: 06 Nov 2020

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Astellas Pharma; Boehringer Ingelheim
  • Class Antihypertensives; Benzimidazoles; Benzoates; Benzothiadiazines; Branched-chain amino acids; Dihydropyridines; Small molecules
  • Mechanism of Action ACE inhibitors; Angiotensin type 2 receptor antagonists; Calcium channel antagonists; Thiazide diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 30 Oct 2020 Astellas Pharma terminates its sales agreement for the Micardis family, prior to October 2020
  • 04 Jan 2018 Chemical structure information added
  • 18 Nov 2016 Launched for Hypertension in Japan (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top